A staging system for histiocytosis X: a Southwest Oncology Group Study.
Patients with generalized histiocytosis X may be divided into three prognostic groups based on age at the time of diagnosis and presence or absence of organ dysfunction. These variables are independent. Favorable response to initial chemotherapy was shown to be associated with improved survival and overall disease control.
D000367:Age Factors; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007223:Infant; D009367:Neoplasm Staging; D011379:Prognosis; D012306:Risk; D014022:Tissue Survival
D000970:Antineoplastic Agents